Key Highlights

  • Novartis terminated a plant contract with Chinese CDMO Porton Pharma Solutions and threatened $64m in legal claims
  • Porton warns the dispute could “adversely impact” its 2026 financial outlook after Novartis walked away from a €50m Investment plan
  • The Swiss drugmaker had planned for Porton to invest €50m in Slovenian facilities as part of the original agreement
  • Industry observers see rising contract disputes as CDMO capacity tightens and pharma firms seek greater control over Supply chains
  • Novartis’ move follows its decision to shutter a German site—cutting 220 jobs—amid broader restructuring of Manufacturing networks

A high-stakes break-up in contract manufacturing

Novartis has escalated a commercial spat with Porton Pharma Solutions by terminating a plant contract and flagging $64m in potential legal claims. The dispute centres on a planned €50m investment by Porton into a new Slovenian Facility intended to support Novartis’s European manufacturing footprint. According to filings reviewed by Fierce Pharma, Novartis unilaterally exited the agreement, citing unspecified “material breaches” by the Chinese contract development and manufacturing organisation (CDMO). Porton, which did not respond to requests for comment, has publicly warned investors that the termination could materially affect its 2026 financial projections—sending shares of the Shanghai-listed firm under pressure in recent trading sessions.

Industry executives say such contract disputes are becoming more frequent as pharmaceutical sponsors tighten control over critical supply chains amid geopolitical and quality-control concerns. “When you see a €50m investment walk away, it signals deeper friction—whether over timelines, quality systems, or strategic alignment,” said an analyst at Jefferies who tracks global CDMO markets. Novartis’s decision to shutter its German plant—eliminating 220 roles—further underscores its broader pivot toward asset-light, outsourced manufacturing models, a trend that has accelerated since the Covid-19 supply-chain disruptions of 2020–21.

The shifting geography of drug production

Porton Pharma Solutions is one of China’s largest publicly traded CDMOs, with a footprint spanning active pharmaceutical ingredient (API) synthesis and finished-dose manufacturing. The company’s decision to pursue European expansion reflects a wider ambition among Chinese CDMOs to diversify beyond domestic markets amid rising US-China trade tensions and increasingly stringent FDA scrutiny of Chinese-made APIs. Yet Novartis’s abrupt exit suggests that even strategic partners are willing to walk away when expectations diverge. “The €50m investment was meant to anchor Porton’s European strategy,” noted a Beijing-based pharma consultant. “If Novartis pulls the plug, it signals that Chinese CDMOs still face credibility hurdles in Western supply chains.”

The episode also echoes Novartis’s recent disposal of a Chinese finished-drug plant to Jiuzhou Pharmaceutical for $15.1m—a transaction that underscores the Swiss giant’s preference for asset-light partnerships over outright ownership in high-risk markets. Analysts at Credit Suisse argue that such moves are part of a deliberate de-risking strategy, “shifting Capital away from greenfield projects toward more flexible, contract-based relationships with proven CDMOs.” However, the legal overhang from the Porton dispute may complicate Novartis’s broader outsourcing push, particularly as it seeks to rationalise its €2.5bn global manufacturing footprint.

Legal exposure and investor fallout

Porton Pharma Solutions has not detailed the specific grounds for its potential $64m counterclaim, but industry precedents suggest disputes often revolve around termination clauses, milestone payments, or intellectual-property indemnification. “A $64m claim is material for a company with a Market Capitalisation of roughly $1.8bn,” said an analyst at UBS who covers Chinese healthcare. “It could force Porton to set aside cash reserves or delay expansion plans in Europe.” Porton’s shares fell 4.2% in Shanghai on the day the news broke, though they have since pared losses amid broader market sentiment.

Legal experts caution that cross-border contract disputes between pharma sponsors and CDMOs can drag on for years, particularly when Jurisdiction and enforcement mechanisms differ. “Novartis is a Swiss company litigating in China against a Chinese supplier—venue and choice-of-law clauses will be pivotal,” explained a partner at an international arbitration practice. Should Porton pursue arbitration under the China International Economic and Trade Arbitration Commission, Novartis may find itself constrained by narrower damages caps than those available in Swiss or EU courts. Meanwhile, investors are left parsing whether the dispute is an isolated contract hiccup or the first tremor of a broader retrenchment by Western pharma from Chinese manufacturing partnerships.

Broader supply-chain fragmentation

The Novartis-Porton rupture fits a wider pattern of supply-chain fragmentation that has reshaped global pharmaceutical manufacturing since the Pandemic. Data from the IQVIA Institute show that China’s share of global API production rose from 31% in 2010 to 43% in 2023, yet Western regulators have grown wary of single-source dependencies. The FDA now lists 187 Chinese API facilities under enhanced surveillance, up from 12 in 2018. “Regulatory Risk is the silent tax on global CDMO relationships,” said a former FDA investigator. “Even if Porton’s quality systems are up to standard, perceptions of risk can derail partnerships.”

Novartis itself has been recalibrating its footprint: it recently offloaded a €15.1m plant in Zhongshan to Jiuzhou Pharmaceutical and is closing a €50m facility in Germany while cutting 220 jobs. These moves align with a broader industry shift toward “China+1” strategies, where sponsors maintain limited exposure to Chinese manufacturing while building redundancy in India, Europe, or North America. Yet the Porton dispute shows that even “China+1” models are not immune to friction. “If Novartis cannot trust a €50m investment in Slovenia with a top-tier Chinese CDMO, where *can* it trust?” asked a supply-chain consultant. The answer may lie in further consolidation among Western CDMOs or a retreat to fully owned, vertically integrated plants—both of which could raise costs and slow Drug Development timelines.

What’s next for Novartis and Porton

For Novartis, the immediate priority is likely to secure alternative manufacturing capacity in Europe—either through existing CDMO relationships or by accelerating plans to repurpose internal Assets. The company’s 2026 outlook, already shaped by Patent expirals and cost-cutting, now faces added uncertainty from the legal dispute. Porton Pharma Solutions (SHA: 603658.SS), meanwhile, must decide whether to escalate the matter to arbitration or seek a negotiated settlement that preserves its European ambitions. Analysts at Bernstein warn that further delays could prompt Porton to revisit its 2026 guidance, which currently assumes steady growth in both domestic and international markets.

Longer term, the episode may accelerate a bifurcation in the CDMO market: Western sponsors gravitate toward EU- or US-registered CDMOs with robust compliance histories, while Chinese CDMOs double down on domestic and emerging-market clients. “The €50m investment was supposed to be a bridgehead,” said a former Novartis executive. “Instead, it has become a cautionary tale.” Whether other sponsors follow Novartis’s lead remains an open question. One biotech CEO with operations in China noted, “If a $64m claim can derail a strategic Partnership, then every contract just got riskier—and more expensive.”